Advancing Therapies for Patients

Find a clinical trial

page image

Open Clinical Trials

shadow image

Text Size

minus image

plus image

plus image

Print

Print image

Email a Friend

You are here: SCRI-UK

/Open Clinical Trials

Find a clinical trial

Open Clinical Trials

All of our clinical trials are listed on this page.  Click the arrow button on the right to see more details about that trial on ClinicalTrials.gov, a database of publicly and privately supported clinical trials around the world.

If you are a patient interested in taking part in a clinical trial, please speak to your doctor or cancer specialist.  If you are a doctor and have a patient you believe may be eligible for an ongoing clinical trial, please do not hesitate to contact us, or click here to access the Sarah Cannon Research Institute UK Patient Referral document.

 

Open and Recruiting

Irreversible BTK Inhibitor

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma (LYM 141)

 

Phase I

PI3K Beta Inhibitor

A Phase I/IIa, First Time in Human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumours with PTEN deficiency

BRAF Inhibitor

An Open-Label, International, Multicenter, Dose-Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed-and–Refractory Multiple Myeloma

BRAF (V600) Inhibitor

A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects with V600 BRAF Mutation-Positive Tumors: an open-label, dose escalating safety lead-in study followed by a single-sequence, placebo-controlled, single-blind study

CAELYX ® Bioequivalence

A Pivotal Bioequivalence Study of DOXIL®/CAELYX® Manufactured at a New Site in Subjects with Advanced or Refractory Solid Malignancies including Subjects with Ovarian Cancer 

PDL1 Inhibitor

Phase I Study of Single Agent MK 3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (REFMAL 306)

ALK Inhibitor

A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas (REFMAL 290)

FAK/MEK Inhibitor

A Phase 1b, multi-center, open-label, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors

FGFR1 Inhibitor

Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate the Safety, Tolerability, and Preliminary Activity of GSK3052230 Alone or in Combination with Paclitaxel and Carboplatin, or Docetaxel, or Aromatase Inhibitor in Subjects with FGFR1 amplified Solid Malignancies (REFMAL 322)

anti PD-L1 Inhibitor

A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications (REFMAL 312)

FGFR Inhibitor

A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors or Multiple Myeloma with FGF/FGFR-Related Abnormalities (REFMAL 340)

AR Inhibitor

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients with Advanced Solid Tumours where the Androgen Receptor Pathway is a Potential Factor (REFMAL 345)

PI3K Inhibitor

A Phase I pharmacodynamic study of copanlisib (BAY 80-6946) as monotherapy in patients with non-Hodgkin’s lymphomas and solid tumors (LYM 97)

FASN Enzyme Inhibitor

A Phase I, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors (REFMAL 323)

 

PI3K alpha/delta inhibitor

A Phase I pharmacodynamic study of copanlisib (BAY 80-6946) as monotherapy in patients with non-Hodgkin’s lymphomas and solid tumors

anti PD-L1

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors [expansion phase only - MULTI 02]

MEK inhibitor

A Phase I/ II Study of LNP3794 in Patients with Advanced Solid Tumors having RAS/BRAF Mutations (REFMAL 356)

PI3K alpha/delta inhibitor

A Phase I pharmacodynamic study of copanlisib (BAY 80-6946) as monotherapy in patients with non-Hodgkin’s lymphomas and solid tumors (LYM 97)

ATR protein kinase inhibitor

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma (REFMAL 385)

Adjuvant PD-L1

A Study comparing the efficacy and safety of atezolizumab (MPDL3280A) versus observation in participants with bladder cancer with risk features for recurrence after cystectomy (GU 125)

ATR inhibitor

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (REFMAL 413)

RAF and MEK inhibitor

A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies (REFMAL 414)

anti PD-L1 inhibitor

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer [LUN 320]

anti PD-L1 inhibitor

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES [REFMAL 434]

cMet RTK inhibitor

A phase I, multicentre, open-label, single-sequence drug:drug interaction study to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumours [REFMAL 436]

Anti-CTLA-4 Antibody

A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors [REFMAL 444]

HUMAX-TF-ADC

First In Human, Dose-Escalating safety study of Tissue Factor Specific Anitbody Drug Conjugate (HUMAX-TF-ADC) In Patients With Locally Advanced and/or Metastatic Solid Tumors Known To Express Tissue Factor [MULTI 06]

ASO- selective degrader of the KRAS primary transcript

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients with Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour

Survival (REFMAL 484)

 

Colorectal

RAF/MEK/ERK pathway Inhibitors

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib +
Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional
5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer (GI 236)

 

Diffuse Large B-cell Lymphoma

anti PD-L1 inhibitor

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (LYM112)

anit PD-L1 inhibitor

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma [LYM 112]

Glycoengineered antibody

A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA (LYM 113)

Glycoengineered Antibody

A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA [LYM 113]

 

CLL

PI3K Inhibitor

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Irreversible BTK Inhibitor

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL 44)

 

Melanoma

Autologous Tumor Infiltrating Lymphocytes

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma (MEL 56)

BRAF/MEK-Inhibitor

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD)

MEK Inhibitor

An open label, randomized Phase 2 trial of the MEK inhibitor Pimasertib or Dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma

MEK inhibitor

A Phase I/ II Study of LNP3794 in Patients with Advanced Solid Tumors having RAS/BRAF Mutations (REFMAL 356)

PI3K beta inhibitor

A Ph. I/IIa, first time in human, dose-escalation study of GSK2636771 in subjects with advanced solid tumours with PTEN deficiency

BRAF Inhibitor

A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects with V600 BRAF Mutation-Positive Tumors: an open-label, dose escalating safety lead-in study followed by a single-sequence, placebo-controlled, single-blind study

BRAF Inhibitor

An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects with BRAF V600 Mutation Positive Tumors (REFMAL 370)

 

Gastric

Monoclonal Antibody

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) (GI 230)

anti PD-L1 inhibitor

A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE -180) [GI 227]

MGC

RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC GASTRIC CANCER REFRACTORY TO STANDARD TREATMENTS (GI 229)

MEK inhibitor **NEW**

A Phase 1/2 Study of LNP3794 in Patients with Advanced Solid Tumors having RAS/BRAF Mutations

anti PD-L1

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications (REFMAL 312)

PI3K beta inhibitor

A Ph1/2a, first time in human, OL dose-esc study of GSK2636771 in subjects with advanced solid tumours with PTEN deficiency

JAK1/2 Inhibitor

A Randomized, Double-Blind, Phase III Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (GI 204)

anti PD-L1

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium (MULTI 04)

AKT Inhibitor

A Phase II study of GDC-0068 in combination with Fluoropyrimidine plus Oxaliplatin versus placebo with Fluoropyrimidine plus Oxaliplatin in patients with locally advanced or metastatic gastric or gastrooesophageal junction adenocarcinoma

HER2/HER3 Bi-Specific Antibody

A Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients With HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

 

NHL

ALK/ TRK inhibitor

A Phase I/ IIa, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas

PI3K Inhibitor

A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma (LYM 87)

Fc-optimized human mAb against CD19

A Phase II, Single Arm Open-Label, Multicenter Study to evaluate safety and clinical efficacy of Lenalidomide combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large Bcell Lymphoma (RR-DLBCL) (LYM 109)

 

Prostate

AR anti-androgen

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of the investigational agent Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Low Volume Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (GU 130)

Anti-PD-L1 Antibody

A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN (GU 139)

Parp inhibitor

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (GU 142)

Parp inhibitor

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (GU 146)

AKT/ PI3K inhibitor

A Phase Ib/II Study of GDC-0068 or GDC-0980 with Abiraterone Acetate Versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy

AR Antagonist

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (GU 101)

AR antagonist

A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) (GU 121)

AR antagonist

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients with Advanced Solid Tumours where the Androgen Receptor Pathway is a Potential Factor (REFMAL 345)

 

Breast

PARP Inhibitor

A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician’s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease (BRE 237)

EGFR/ pan-HER2 inhibitor

A Phase I/ II, multi-centre, open-label study in patients with HER2 positive breast cancer to assess the tolerability and safety of daily oral administration of S-222611 in combination with various standard anticancer treatments and to examine the potential for pharmacokinetic interactions [Phase II] (REFMAL 342)

Nab-Paclitaxel (Abraxane®)

A phase 2/3, multi-center, open-label, randomized study of weekly nab®-Paclitaxel in combination with Gemcitabine or Carboplatin, compared to Gemcitabine/Carboplatin, as first line treatment in subjects with ER, PgR and HER2 negative (triple negative) metastatic breast cancer (BRE 223)

AR antagonist

A Phase I (first-time-in-man), Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients with Advanced Solid Tumours where the Androgen Receptor Pathway is a Potential Factor

PI3K beta inhibitor

A Ph I/ IIa, first time in human, OL dose-esc study of GSK2636771 in subjects with advanced solid tumours with PTEN deficiency

Tyrosine kinase inhibitor vs anti-HER2 antibody

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (BRE 271)

CDK4/6 inhibitor

Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in
Combination with Fulvestrant in Patients with Hormone Receptor-Positive,
HER2-Negative Locally Advanced or Metastatic Breast Cancer after Endocrine Failure (BRE 282)

ATP-competitive inhibitor of CD K4 and CDK6

A Randomized, Open-Label, Phase 3 Study of Abemaciclib
Combined with Standard Adjuvant Endocrine Therapy versus
Standard Adjuvant Endocrine Therapy Alone in Patients with
High Risk, Node Positive, Early Stage, Hormone Receptor
Positive, Human Epidermal Receptor 2 Negative, Breast
Cancer (BRE 296)

mTOR inhibitor

A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR) (BRE 253)

mTOR inhibitor

A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR) (BRE 253)

Tyrosine kinase inhibitor

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements [MULTI 05]

ER Antagonist

A Phase II, open-label, randomized Study of gdc-0810 versus fulvestrant in POSTMENOPAUSAL WOMEN WITH advanced or metastatic ER+/HER2- breast cancer resistant to aromatase inhibitor therapy (BRE 266)

MEK inhibitor

A MULTISTAGE, PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB IN COMBINATION WITH PACLITAXEL AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER [BRE 276]

ATR inhibitor/ WEE1 Inhibitor

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the
Safety and Efficacy of Agents Targeting DNA Damage Repair in
Combination with Olaparib versus Olaparib Monotherapy in the Treatment
of Metastatic Triple Negative Breast Cancer Patients Stratified by
Alterations in Homologous Recombinant Repair (HRR)-related Genes
(including BRCA1/2) (BRE309)

 

Ovarian

WEE1 kinase inhibitor

A Multicentre Phase II Study of AZD1775 plus Chemotherapy in Patients
with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary
Peritoneal Cancer (GYN49)

MEK Inhibitor

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (GYN 48)

Antibody-Drug Conjugate

A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of DNIB0600a compared to pegylated liposomal doxorubicin administered intravenously to patients with platinum-resistant ovarian cancer

PARP Inhibitor

A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Ovarian Cancer or Other Solid Tumour

PARP Inhibitor

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum Sensitive High-Grade Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

 

Lung

PD-1 inhibitor

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer

MEK inhibitor

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination with First Line Chemotherapy Regimens in Patients with Non-Small Cell Lung Cancer (NSCLC) [Continous & Intermittant Dosing] (GYN 48)

HER3 inhibitor

Phase  III, Randomized, Placebo Controlled, Double Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wild-Type subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed on at least One prior systemic Therapy (LUN 281)

EGFR inhibitor

A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3) (LUN 285)

 

MEK inhibitor

A Phase 1/2 Study of LNP3794 in Patients with Advanced Solid Tumors having RAS/BRAF Mutations (REFMAL 356)

FGFR inhibitor

Multi-arm, Non-randomized, Open Label Phase IB Study to Evaluate the Safety, Tolerability, and Preliminary Activity of GSK3052230 Alone or in Combination with Paclitaxel and Carboplatin, or Docetaxel, or Aromatase Inhibitor in Subjects with FGFR1 amplified Solid Malignancies

FAK/MEK inhibitor

A Phase 1b, multi-center, open-label, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors

ALK/ TRK inhibitor

A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas

BRAF Inhibitor

A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects with V600 BRAF Mutation-Positive Tumors: an open-label, dose escalating safety lead-in study followed by a single-sequence, placebo-controlled, single-blind study

PI3K beta inhibitor

A Ph1/2a, first time in human, OL dose-esc study of GSK2636771 in subjects with advanced solid tumours with PTEN deficiency

anti PD-L1

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC -LUN 282)

cMet RTK inhibitor

A phase II, multicentre, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease (LUN 306)

Potential CYP2C8 and CYP3A4 inhibitor

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial) (LUN 337)

anti PD-L1

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium (MULTI 04)

HUMAX-TF-ADC

First In Human, Dose-Escalating safety study of Tissue Factor Specific Anitbody Drug Conjugate (HUMAX-TF-ADC) In Patients With Locally Advanced and/or Metastatic Solid Tumors Known To Express Tissue Factor [MULTI 06]

cMet RTK inhibitor

A phase II, multicentre, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease [LUN 306]

mitotic inhibitor

A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO ASSESS SAFETY AND EFFICACY OF NAB®-PACLITAXEL (ABI-007) WITH EPIGENETIC MODIFYING THERAPY OF CC-486,  AND NAB®-PACLITAXEL MONOTHERAPY AS SECOND-LINE TREATMENT IN SUBJECTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): ABOUND.2L (LUN 316)

anti PD-L1 inhibitor

A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) [LUN 325]

ALK Inhibitor

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC) (LUN 322)

anti PD-L1

A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at east Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARTIC -LUN 283)

anti PD-L1

A Phase III, Open-Label, Randomized study of MPDL3280A (Anti−PDL1 ANTIBODY) Compared with Cisplatin or Carboplatin +Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients With Stage IV Non-Squamous Non−Small Cell Lung Cancer (LUN 296)

anti PD-L1

A Phase III, Open-Label, Randomized study of MPDL3280A (Anti−PDL1 ANTIBODY) Compared with Gemcitabine+Cisplatin or Carboplatin for PD-L1−Selected Chemotherapy Naive Patients With Stage IV Squamous Non−Small Cell Lung Cancer (LUN 297)

 

Renal

ADC

A 3-Arm Phase 2 Double-Blind Randomized StudY of Gemcitabine, Abraxane® Plus PlacebO versuS GEMcitabIne, Abraxane® plus 1 or 2 TruncatEd Courses of Demcizumab in Subjects with 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma (GI 213)

cMet inhibitor

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients with Papillary Renal Cell Carcinoma (PRCC) (GU 111)

PD-1 inhibitor

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma (GU 112)

MET/ VEGFR inhibitor

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy

 

Bladder

PDL1 Inhibitor

A Phase II, single-arm study of MPDL3280A in patients with locally advanced or metastatic urothelial bladder cancer

AR antagonist

A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients with Advanced Solid Tumours where the Androgen Receptor Pathway is a Potential Factor (REFMAL 345)

Adjuvant PD-L1

A Study comparing the efficacy and safety of atezolizumab (MPDL3280A) versus observation in participants with bladder cancer with risk features for recurrence after cystectomy (IMvigor10 / GU 125)

VEGFR-2 inhibitor

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy (GU 120)

anti PD-L1 inhibitor

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY) (GU 118)

PD-1 inhibitor

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY) [GU 118]

HUMAX-TF-ADC

First In Human, Dose-Escalating safety study of Tissue Factor Specific Anitbody Drug Conjugate (HUMAX-TF-ADC) In Patients With Locally Advanced and/or Metastatic Solid Tumors Known To Express Tissue Factor [MULTI 06]

 

Multiple Myeloma

FGFR inhibitor

An open-label, Dose-escalation and Dose-expansion, Phase I/ II Study of TAS-120, Evaluating the Safety, Tolerability, PK, Pharmacodynamic, and Antitumor Activity of TAS-120 in Patients with Advanced Solid Tumors or Multiple myeloma with and without FGF/FGFR-related abnormalities (REFMAL 340)

 

Pancreas

Recombinant human PH20 hyaluronidase enzyme conjugated to polyethylene glycol (PEG)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma [GI 232]

Human tetravalent bi-specific antibody

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-Line Metastatic Pancreatic Cancer (CARRIE)  (GI 214)

 

Solid Tumours

Monoclonal Antibody

A phase 1b/2 open-label study to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics of avelumab* (MSB0010718C) in combination with other cancer immunotherapies in patients with advances malignancies (REFMAL 434)

MEK Inhibitor

A Phase I, open-label study to determine the effect of
repeat dosing of trametinib on the pharmacokinetics of a
combined oral contraceptive (norethindrone plus ethinyl
estradiol) in female patients with solid tumors (REFMAL 491)

Probody-Tx

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept,
First-in-Human Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults
with Metastatic or Locally Advanced Unresectable Solid Tumors
(PROCLAIM-CX-2009) (REFMAL 509)

ATR kinase Inhibitor

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety,
Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of
Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy
and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with
Advanced Solid Malignancies (REFMAL 561)

Chk1 Inhibitor

A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in
Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone
in Subjects with Advanced Cancer (REFMAL 523)

HER2-selective covalent inhibitor

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE
SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT
BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH HER2 OR HER3 ABNORMALITIES (REFMAL 555)

Anti-PD-1 Monoclonal Antibody

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies (REFMAL 391)

Anti-PD-1 Monoclonal Antibody

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors (REFMAL 512)

anti-PD-L1 antibody +anti-cytotoxic T-lymphocyte antigen 4 antibody

An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab +
Tremelimumab Combination Therapy or Durvalumab Monotherapy in
Advanced Solid Malignancies (STRONG) (MULTI-25)

CHK1 Inhibitor

A Phase 1 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer (REFMAL-522)

Anti-PD-1 Monoclonal Antibody

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors (MULTI-14)

Anti PD-L1A

A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancers (REFMAL 459)

FGFR, VEGFR, RET inhibitor

Safety and tolerability of single and repeated doses of ODM-203: an open-label, non-randomised, uncontrolled, dose escalation, multicentre, first in-human study in subjects with advanced solid tumours (REFMAL 469)

PD L1 ProbodyTM therapeutic

An Open Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic, CX-072, as Monotherapy and in Combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in Subjects with Advanced or Recurrent Solid Tumours or Lymphomas (REFMAL 477)

HSP90 inhibitor

A Phase IA/IB Study evaluating TAS-116 in Patients with Advanced Solid Tumors (REFMAL 499)

Tyrosine kinase inhibitor

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements [MULTI 05]

Bruton's tyrosine kinase (Btk) inhibitor

Phase 1b/2 study in multiple gastrointestinal and genitourinary solid tumours [MULTI 08]

FGFR inhibitor

A dose-finding phase I study of TAS-120 in patients with advanced solid tumors with or without fibroblast growth factor/receptor (FGF/FGFR)-related abnormalities followed by a phase 2 study in patients with advanced solid tumors or multiple myeloma with FGF/FGFR-related abnormalities (REFMAL 340)

 

Endometrial

HUMAX-TF-ADC

First In Human, Dose-Escalating safety study of Tissue Factor Specific Anitbody Drug Conjugate (HUMAX-TF-ADC) In Patients With Locally Advanced and/or Metastatic Solid Tumors Known To Express Tissue Factor [MULTI 06]

 

Cervix

HUMAX-TF-ADC

First In Human, Dose-Escalating safety study of Tissue Factor Specific Anitbody Drug Conjugate (HUMAX-TF-ADC) In Patients With Locally Advanced and/or Metastatic Solid Tumors Known To Express Tissue Factor [MULTI 06]

Autologous Tumor Infiltrating Lymphocytes

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous
Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or
Persistent Cervical Carcinoma (GYN 76)

 

Esophageal

HUMAX-TF-ADC

First In Human, Dose-Escalating safety study of Tissue Factor Specific Anitbody Drug Conjugate (HUMAX-TF-ADC) In Patients With Locally Advanced and/or Metastatic Solid Tumors Known To Express Tissue Factor [MULTI 06]

anti PD-L1 inhibitor

A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians's Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181) [GI 228]

 

hepatic

Anti-PD-1 Monoclonal Antibody

A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously Treated Hepatocellular Unresectable Carcinoma [GI 270]

Please also visit www.clinicaltrials.gov. Click here to access the SCRUK Patient Referral document.

Latest Videos

watch the latest videos.

Learn more

News

news from the industry.

Read more

hero1 image
Sarah Cannon Research UK NHS Ventures
University College London Hospitals
LOC